GleamWall
中文EN

LGVN Longeveron Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1721484 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-18.9%
TTM net income YoY-4.9%
TTM EPS YoY134.5%
Revenue 3-yr CAGR15.0%
Net income 3-yr CAGR—

Margins

Gross margin66.4%
Operating margin-2,020.8%
Net margin-1,921.7%
FCF margin-1,560.1%
EBITDA margin-1,952.1%

Returns

ROE-305.1%
ROA-162.4%
ROIC (approx.)—
Asset turnover0.08x

Leverage & solvency

Liabilities / assets60.8%
Debt / equity0.00x
Current ratio1.25x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.80x
Accruals ratio-31.8%
Payout ratio—
Capex / revenue14.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$115,000$287,000$398,000$365,000$137,000$316,000$381,000$603,000
Cost of revenue$44,000$105,000$134,000$108,000$12,000$170,000$106,000$73,000
Gross profit$71,000$182,000$264,000$257,000$125,000$146,000$275,000$530,000
R&D expense$3.96M$3.19M$2.32M$2.72M$3.85M$2.95M$2.52M$1.99M
SG&A expense$3.31M$3.16M$2.72M$2.94M$3.58M$2.59M$2.94M$2.82M
Operating income-$7.20M-$6.17M-$4.78M-$5.40M-$7.31M-$5.40M-$5.18M-$4.28M
Income tax$0$0$0$0$0$0$0$0
Net income-$6.13M-$6.07M-$4.74M-$5.44M-$7.22M-$5.03M-$5.01M-$4.08M
EBITDA-$7.00M-$5.97M-$4.58M-$5.20M-$7.11M-$5.20M-$4.98M-$4.08M
EPS (basic)-1.91-0.19-0.19—-3.93-0.33-0.34—
EPS (diluted)-1.91-0.19-0.19—-3.93-0.33-0.34—
Weighted avg. shares (diluted)3.21M31.38M24.79B—1.84M15.01M14.95B—
Balance sheet
Cash & equivalents$7.25M$10.08M$15.76M$4.66M$9.24M$10.33M$14.33M$19.23M
Short-term investments——————$0$0
Receivables$64,000$65,000$68,000$104,000$52,000$31,000$29,000$84,000
Current assets$8.15M$11.32M$16.86M$5.45M$10.34M$11.27M$15.28M$19.62M
PP&E, net$1.45M$1.60M$1.65M$1.84M$2.12M$2.26M$2.29M$2.45M
Intangibles$2.17M$2.20M$2.24M$2.29M$2.31M$2.32M$2.29M$2.40M
Total assets$12.02M$15.49M$21.21M$10.26M$15.56M$16.75M$20.85M$25.56M
Current liabilities$6.53M$4.31M$4.34M$4.09M$4.94M$3.28M$2.72M$2.58M
Total liabilities$7.30M$5.08M$5.18M$4.59M$5.59M$4.09M$3.69M$3.67M
Shareholders' equity$4.71M$10.40M$16.03M$5.67M$9.97M$12.66M$17.16M$21.89M
Cash flow statement
Operating cash flow-$2.69M-$5.65M-$4.37M-$5.30M-$5.05M-$3.60M-$4.70M-$3.37M
Capital expenditure$65,000$103,000$0$0$57,000$161,000$27,000$13,000
Free cash flow-$2.75M-$5.76M-$4.37M-$5.30M-$5.11M-$3.76M-$4.72M-$3.39M
Investing cash flow-$66,000-$103,000-$20,000-$64,000-$118,000-$263,000-$150,000-$123,000
Financing cash flow-$78,000$75,000$15.49M$777,000$4.08M-$133,000-$58,000-$50,000
Depreciation & amortization$200,000$200,000$200,000$200,000$200,000$200,000$200,000$200,000
Stock-based compensation$520,000$373,000$379,000$376,000$448,000$513,000$340,000$390,000

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.